Sweden rejects prostate cancer screening
This article was originally published in Clinica
Comprehensive screening for early symptoms of prostate cancer cannot be justified at present, Sweden's government committee on the evaluation of medical methodology (SBU) has decided. In the absence of proven diagnostic techniques able to differentiate between tumours which will develop slowly and more aggressive growths, the committee concluded it could not recommend the introduction of a nationwide screening programme, says Lakartidningen (No 21, 1995).
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.